Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains
Dermata Therapeutics, Inc. (NASDAQ: DRMA) has seen a sharp gain in share price; the company is currently trading at $2.18, indicating a stunning 61.48% increase in pre-market activity. This spike comes after the company’s major Phase 3 clinical trial released encouraging early findings. Breakthrough Findings from the XYNGARI Trial The first Phase 3 study of …
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains Read More »